Harvard University
Cambridge, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Stroke
FollowWhat is new in Stroke research, which clinical trials are open, and who works on it. From public registries and PubMed, with the source and date of every fact.
Cure status
- 0.25mg/kg TNKPhase 3 · NCT06994975
- 14-day remote ischemic conditioningPhase 3 · NCT06559241
- 30-day remote ischemic conditioningPhase 3 · NCT06559241
- Acetyl-LeucinePhase 3 · NCT07275749
- AFSW Guided DOACPhase 3 · NCT05836987
- AlbuminPhase 3 · NCT07263308
- Allopurinol 200 mgPhase 3 · NCT05943821
- AlteplasePhase 3 · NCT06658197 · NCT07727395
- Angong Niuhuang Pills (ANP)Phase 3 · NCT07752719
- Antiplatelet therapyPhase 3 · NCT05387954
- Antiplatelet-only strategyPhase 3 · NCT04045665
- ApixabanPhase 3 · NCT07626411 · NCT03907046 · NCT07709780 · NCT07175428 · NCT07471139
- Apixaban 2.5 milligram Oral TabletPhase 3 · NCT05679024
- Apixaban 5 MG Oral TabletPhase 3 · NCT05687448
- ASAPhase 3 · NCT07468448
- AspirinPhase 3 · NCT07746882 · NCT03907046 · NCT07617870 · NCT07540416 · NCT06530537 · NCT06548971
- aspirin 100mgPhase 3 · NCT07275749
- Aspirin 75 mg dailyPhase 3 · NCT07243704
- Aspirin 75 Mg Oral TabletPhase 3 · NCT06591338
- Aspirin 75 to 100mg once a dayPhase 3 · NCT05687448
- Aspirin 75-300mgPhase 3 · NCT05476991
- Aspirin 75mgPhase 3 · NCT06591377
- Aspirin or clopidogrelPhase 3 · NCT07454707
- AtorvastatinPhase 3 · NCT07908875
- Atorvastatin 40 Mg Oral TabletPhase 3 · NCT06360120
- Atorvastatin 40mgPhase 3 · NCT06358313
- Best medical managementPhase 3 · NCT06559241 · NCT07668323
- Biological/Vaccine: PlaceboPhase 3 · NCT07227246
- Both deferoxamine mesylate and colchicinePhase 3 · NCT06352632
- BP lowering drugs (nicardipine, labetalol, urapidil)Phase 3 · NCT06677970
- BP raising drug (phenylephrine) or BP lowering drugs (nicardipine, labetalol, urapidil)Phase 3 · NCT06677970
- ButylphthalidePhase 3 · NCT07252544 · NCT07230587
- Butylphthalide PlaceboPhase 3 · NCT07252544
- BXOS110Phase 3 · NCT07520565
- carbogen with or without phenyleprhinePhase 3 · NCT06770426
- carotid artery stenting during EVTPhase 3 · NCT06511089
- CenvacibartPhase 3 · NCT07876492
- CilostazolPhase 3 · NCT06530537
- Cilostazol 100 MGPhase 3 · NCT06591377 · NCT06919835
- Cilostazol 100 mg TabletsPhase 3 · NCT07174414
- ClopidogrelPhase 3 · NCT07619885 · NCT06601127 · NCT06591338
- Clopidogrel + AspirinPhase 3 · NCT05047172
- Clopidogrel 75 Mg Oral TabletPhase 3 · NCT06360120 · NCT07275749
- Colchicine 0.5 MGPhase 3 · NCT05476991 · NCT06587737 · NCT06763055 · NCT07035405
- Colchicine 0.5 MG Oral TabletPhase 3 · NCT04774159
- Colchicine onlyPhase 3 · NCT06352632
- Colchicine-PlaceboPhase 3 · NCT04774159
- Combination GroupPhase 3 · NCT07369999
- Continuous DOAC therapyPhase 3 · NCT05836987
- Control GroupPhase 3 · NCT07369999
- Control group (Aspirin combined with clopidogrel)Phase 3 · NCT06414499
- Conventional ThrombectomyPhase 3 · NCT07670065
- Deferoxamine MesylatePhase 3 · NCT06763055
- Deferoxamine mesylate onlyPhase 3 · NCT06352632
- Dimephosphon®Phase 3 · NCT07167550
- Direct Angio Suite Acute Stroke Intervention With CT/DSA Hybrid Emergency Stroke UnitPhase 3 · NCT07670065
- Direct oral anticoagulantPhase 3 · NCT05825573
- dl-3-butylphthalidePhase 3 · NCT05976152
- dl-3-butylphthalide placeboPhase 3 · NCT05976152
- Drug Capsule (Valsartan + Amlodipine + Rosuvastatin)Phase 3 · NCT05155137
- Drug: Normal SalinePhase 3 · NCT05691244
- dual antiplatelet therapyPhase 3 · NCT07379190
- Early Angong Niuhuang Pill TreatmentPhase 3 · NCT07784569
- Edaravone Dexborneol Sublingual TabletsPhase 3 · NCT06674460
- Edoxaban 15 mgPhase 3 · NCT07454707
- Endovascular TherapyPhase 3 · NCT07717216
- Endovascular thrombectomyPhase 3 · NCT06760195 · NCT07163299 · NCT06559241 · NCT07389460 · NCT06663631 · NCT07727395 · NCT06987305
- Endovascular treatmentPhase 3 · NCT07263308
- Eptifibatide (Integrilin)Phase 3 · NCT07347626
- FlecainidePhase 3 · NCT05213104
- guideline-recommended SoCPhase 3 · NCT07002476
- High target groupPhase 3 · NCT07242599
- Hybutimibe 10mg QDPhase 3 · NCT07908875
- hypothermiaPhase 3 · NCT06301412
- IA thrombolysisPhase 3 · NCT06352632
- IMP Levodopa 100mg/Carbidopa 25mgPhase 3 · NCT03735901
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mLPhase 3 · NCT05739383
- Intra-arterial infusion of AlteplasePhase 3 · NCT06768138
- Intra-arterial TenecteplasePhase 3 · NCT07357987 · NCT06781385
- Intra-arterial thrombolysisPhase 3 · NCT07469293 · NCT07668323 · NCT07302854
- Intravenous administrationPhase 3 · NCT07603440
- Intravenous placeboPhase 3 · NCT07389460 · NCT06987305
- Intravenous placebo before endovascular thrombectomyPhase 3 · NCT07135089
- Intravenous rhPro-UKPhase 3 · NCT07389460
- Intravenous rhTNK-tPAPhase 3 · NCT06987305
- Intravenous tenecteplasePhase 3 · NCT05199662
- Intravenous tenecteplase (TNK)Phase 3 · NCT07621796
- Intravenous thrombolysisPhase 3 · NCT06760195 · NCT07906275 · NCT06841965 · NCT06841978 · NCT06749834
- Intravenous TirofibanPhase 3 · NCT07335107
- Intravenous tirofiban before endovascular thrombectomyPhase 3 · NCT07135089
- Isosorbide MononitratePhase 3 · NCT07252544
- Isosorbide Mononitrate PlaceboPhase 3 · NCT07252544
- LevetiracetamPhase 3 · NCT06773364
- LNM-navigated cTBSPhase 3 · NCT07645586 · NCT07645560
- Low target groupPhase 3 · NCT07242599
- Low-dose intravenous tenecteplasePhase 3 · NCT06352632
- Magnetic Resonnance Imaging (MRI)Phase 3 · NCT03998852
- Matching placeboPhase 3 · NCT03735901
- Matching Placebo for Recombinant Human ProurokinasePhase 3 · NCT07901842
- Mechanical Endovascular ThrombectomyPhase 3 · NCT07906275
- Mechanical ThrombectomyPhase 3 · NCT07356284
- Mechanical Thrombectomy plus adjunct stentingPhase 3 · NCT07356284
- MetfominPhase 3 · NCT07899307
- MethylprednisolonePhase 3 · NCT04873583
- Methylprednisolone sodium succinatePhase 3 · NCT06360458 · NCT07202143
- Methyprednisolone sodium succinatePhase 3 · NCT06870448
- MilvexianPhase 3 · NCT05702034
- Minocycline Hydrochloride Capsule (50 mg per capsule)Phase 3 · NCT07526987
- Modafinil 200mgPhase 3 · NCT06354985
- MT alonePhase 3 · NCT07603440
- MT+CAS with IV-APPhase 3 · NCT05611242
- MT+CAS with PO-APPhase 3 · NCT05611242
- MT+CAT with PO-APPhase 3 · NCT05611242
- NaCl 0.9% 100mlPhase 3 · NCT06447701
- Nitrogen-oxygen breathing mixturePhase 3 · NCT07200180
- No thrombolysis (thrombectomy alone)Phase 3 · NCT07748039
- non-immunogenic staphylokinasePhase 3 · NCT07324837
- NoNO-42Phase 3 · NCT06352632 · NCT06403267
- Normal SalinePhase 3 · NCT07030621 · NCT07497542 · NCT07202143
- NT 201Phase 3 · NCT03992404
- Optional interventionPhase 3 · NCT05943821
- Oral Anticoagulant plus background antiplatelet therapyPhase 3 · NCT04045665
- Oral Anticoagulant, Direct-ActingPhase 3 · NCT05387954
- OrforglipronPhase 3 · NCT07241390
- Oxygen (Normobaric Hyperoxia)Phase 3 · NCT07717216
- Pelacarsen (TQJ230)Phase 3 · NCT07517263
- Peripheral intravenous norepinephrinePhase 3 · NCT06059144
- phenylephrinePhase 3 · NCT06770426
- PolycapPhase 3 · NCT05963568
- Positron Emission Tomography (PET) with [18F]-FDOPAPhase 3 · NCT03998852
- Positron Emission Tomography (PET) with [18F]-FEOBVPhase 3 · NCT03998852
- PPA InterventionPhase 3 · NCT06863571
- PrednisolonePhase 3 · NCT04873583
- Primary intra-arterial thrombolysisPhase 3 · NCT07137832
- ProbucolPhase 3 · NCT06225752
- propofol (drug)Phase 3 · NCT07902791
- Recaticimab (intensive)Phase 3 · NCT07002476
- Recombinant Activated Factor VII (rFVIIa)Phase 3 · NCT03496883
- Recombinant Factor VIIaPhase 3 · NCT07227246
- Recombinant Human Prourokinase for Injection (rhPro-UK)Phase 3 · NCT07776873 · NCT07901842
- Recombinant Tissue Plasminogen Activator (rt-PA)Phase 3 · NCT07668323
- REGN7508Phase 3 · NCT07626411 · NCT07430956 · NCT07175428
- REGN9933Phase 3 · NCT07430956 · NCT07175428
- Remote Ischemic ConditioningPhase 3 · NCT07531394
- Rescue therapyPhase 3 · NCT07668323
- RetatrutidePhase 3 · NCT06383390
- Reteplase 10 Units (U) plus a second dose of reteplase 10 UPhase 3 · NCT07748039
- rhPro-UKPhase 3 · NCT07617870
- rhTNK-tPAPhase 3 · NCT07201688 · NCT06414499
- rhTNK-tPA (0.25mg/kg)Phase 3 · NCT07748039
- RivaroxabanPhase 3 · NCT07468448 · NCT04755283
- Rivaroxaban + AspirinPhase 3 · NCT05047172
- Rivaroxaban, or Edoxaban , or Apixaban , or DabigatranPhase 3 · NCT07746882
- Rosuvastatin 20mgPhase 3 · NCT06358313 · NCT06360120
- Semaglutide 0.5 mgPhase 3 · NCT07030621 · NCT06788626
- Semaglutide 2.4mgPhase 3 · NCT06909006
- Semaglutide placeboPhase 3 · NCT06909006
- Sentagliptin Phosphate - single dosePhase 3 · NCT07241897
- SevofluranePhase 3 · NCT07902791
- SGLT-2 inhibitorsPhase 3 · NCT07105917
- SHPL-49 InjectionPhase 3 · NCT07241520
- Shuxuening InjectionPhase 3 · NCT06157502
- SonlicromanolPhase 3 · NCT06451757
- SovateltidePhase 3 · NCT05691244
- SP-8203Phase 3 · NCT06660719
- Standard Medical ManagementPhase 3 · NCT07476898 · NCT07357987
- Standard Medical TherapyPhase 3 · NCT07347626 · NCT07335107
- Standard medical treatmentPhase 3 · NCT07047014 · NCT06994975 · NCT07168278 · NCT06954155 · NCT07606807 · NCT07302854
- Standard-dose intravenous tenecteplasePhase 3 · NCT06352632
- Sulfur HexafluoridePhase 3 · NCT05648812
- Surgical bundlePhase 3 · NCT07784569
- Tegoprazan 50 mgPhase 3 · NCT07687706
- TenecteplasePhase 3 · NCT07361302 · NCT05105633 · NCT07375966 · NCT06949228 · NCT06658197 · NCT07375953 · NCT05199194 · NCT06320431
- Tenecteplase (0.0938mg/kg)Phase 3 · NCT07471282
- Tenecteplase (0.25mg/kg)Phase 3 · NCT07047014 · NCT07476898 · NCT06954155
- Tenecteplase (rhTNK-tPA) (0.25 mg/kg, to maximum of 25mg)Phase 3 · NCT07912970 · NCT07606807
- Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)Phase 3 · NCT07073469 · NCT07092709 · NCT07475949 · NCT07253181 · NCT06801054
- Tenecteplase or Alteplase- depending upon availability at each treating centrePhase 3 · NCT07687056
- Tenecteplase/Alteplase- depending upon availability at each treating centrePhase 3 · NCT07906275
- The ClopidogrelPhase 3 · NCT06853535
- The methylprednisolone sodium succinatePhase 3 · NCT07141303
- The ticagrelorPhase 3 · NCT06853535
- thrombolysis therapyPhase 3 · NCT06878066
- Ticagrelor + AspirinPhase 3 · NCT05047172
- Ticagrelor 90 MGPhase 3 · NCT06591377 · NCT06591338
- Ticagrelor 90mgPhase 3 · NCT05476991
- TirofibanPhase 3 · NCT07537933 · NCT06319846 · NCT07111806 · NCT07379190
- Tirofiban HydrochloridePhase 3 · NCT05604638
- TNKPhase 3 · NCT07168278 · NCT06696131
- TNK-tPAPhase 3 · NCT07540416
- TocilizumabPhase 3 · NCT07509645 · NCT07263776 · NCT06447701
- Transcatheter PFO closurePhase 3 · NCT05387954
- Transcranial Direct Current StimulationPhase 3 · NCT07496645 · NCT06764797
- Transcranial Direct Current Stimulation compined with virtual reality based mirror therapyPhase 3 · NCT06764797
- Treatment of edaravone dexborneol sublingual tablets containin edaravone 30 mg plus borneol 6 mg, twice daily (with an interval of ≥6 hours between doses) for three months.Phase 3 · NCT07604350
- Virtual realityPhase 3 · NCT06764797
- Vitamin K antagonistPhase 3 · NCT05825573
- WarfarinPhase 3 · NCT07709780 · NCT07471139
- Y-6Phase 3 · NCT07040085
- Y-6 placeboPhase 3 · NCT07040085
- Yiqi Huayu Jiedu MixturePhase 3 · NCT07784569
- ZastaprazanPhase 3 · NCT07730840
- Аrgon-oxygen breathing mixturePhase 3 · NCT07200180
- 2mg BaricitinibPhase 2/3 · NCT07449910
- 4mg BaricitinibPhase 2/3 · NCT07449910
- Botulinum toxin type APhase 2/3 · NCT06296082
- Bovis Calculus Stativus (BCS)Phase 2/3 · NCT07240467
- corresponding control group sequential interventionPhase 2/3 · NCT07591883
- Dengzhan Shengmai - Erigeron breviscapus sequential interventionPhase 2/3 · NCT07591883
- DulaglutidePhase 2/3 · NCT07282041
- Early Resumption of Oral Anticoagulation TherapyPhase 2/3 · NCT06696079
- edoxabanPhase 2/3 · NCT06900725
- Edoxaban 30 mgPhase 2/3 · NCT06900725
- Empagliflozin 10 MGPhase 2/3 · NCT06715449
- GalantaminePhase 2/3 · NCT07003386
- Intra-arterial tenecteplase injection at the completion of thrombectomyPhase 2/3 · NCT05892510
- JX10Phase 2/3 · NCT06990867
- KetaminePhase 2/3 · NCT03223220
- Late Resumption of Oral Anticoagulation TherapyPhase 2/3 · NCT06696079
- Midazolam injectionPhase 2/3 · NCT03223220
- Minocycline 200mgPhase 2/3 · NCT07237048
- Minocycline hydrochloride capsulePhase 2/3 · NCT07594314 · NCT07594301
- MLC1501Phase 2/3 · NCT05046106
- MSC, marrowPhase 2/3 · NCT07831746
- Neuroncell-EXPhase 2/3 · NCT06129175
- Non-invasive transcranial Temporal Interference Stimulation (iTBS-tTIS Striatum)Phase 2/3 · NCT07792811
- Non-invasive transcranial Temporal Interference Stimulation sham-tTIS Striatum)Phase 2/3 · NCT07792811
- PCSK9 inhibitorPhase 2/3 · NCT07174375
- Recombinant human tissue kallikreinPhase 2/3 · NCT05065216
- SIM0811 Dose Level A (Phase II)Phase 2/3 · NCT07903701
- SIM0811 Dose Level B (Phase II)Phase 2/3 · NCT07903701
- SIM0811 Dose Level C (Phase II)Phase 2/3 · NCT07903701
- SIM0811（Phase III）Phase 2/3 · NCT07903701
- Standard treatment for acute ischemic strokePhase 2/3 · NCT07003386
- tDCSPhase 2/3 · NCT07334977 · NCT07688551
- Ticagrelor 60 + AspirinPhase 2/3 · NCT06653348
- Ticagrelor 90 + aspirinPhase 2/3 · NCT06653348
- Tirofiban InjectionPhase 2/3 · NCT07842185
- TirzepatidePhase 2/3 · NCT07734792
- TociliuzumabPhase 2/3 · NCT07870681
- Transcutaneous spinal cord stimulationPhase 2/3 · NCT06596369
- [18F]AlF-OCPhase 2 · NCT07104487
- 10% Fructose InjectionPhase 2 · NCT07626541
- 20% human serum albuminPhase 2 · NCT07365475
- AbelacimabPhase 2 · NCT04755283
- Adjusted BP management groupPhase 2 · NCT07279259
- Administration of BMS-986368Phase 2 · NCT07704840
- air/oxygenPhase 2 · NCT04696523
- AKL-T01Phase 2 · NCT05507138
- Albumin infusionPhase 2 · NCT07415655
- AleetoPhase 2 · NCT06759753
- AlirocumabPhase 2 · NCT05001984
- ALT001Phase 2 · NCT07841496
- AmantadinePhase 2 · NCT05140148
- Androtriol Injection (High-dose group)Phase 2 · NCT06679322
- Androtriol Injection (Low-dose group)Phase 2 · NCT06679322
- Anisodine HydrobromidePhase 2 · NCT07513233 · NCT07800572
- Anisodine Hydrobromide PlaceboPhase 2 · NCT07800572
- BB-031Phase 2 · NCT06226805
- Bevifibatide citrate injectionPhase 2 · NCT06712004
- Capsaicin Transmucosal Oral FilmPhase 2 · NCT07406971
- CC-101 (f/k/a NR1) Intracerebral TransplantationPhase 2 · NCT07709845
- Cerebello-spinal direct current stimulationPhase 2 · NCT07073287
- CerebrolysinPhase 2 · NCT06339411
- Conventional Tongue-Pressure Resistance TrainingPhase 2 · NCT07798401
- Digital Intelligent Tongue-Pressure Biofeedback Resistance TrainingPhase 2 · NCT07798401
- Dornase AlfaPhase 2 · NCT05880524
- DRFPhase 2 · NCT07275515
- Edaravone dexborneol sublingual tabletPhase 2 · NCT06315231
- Escitalopram 10mgPhase 2 · NCT03843463
- EtavopivatPhase 2 · NCT05953584
- HEAD DOWN TILT -10° to -15°Phase 2 · NCT06297863
- High frequency repetitive transcranial magnetic stimulationPhase 2 · NCT05584124
- High-definition Cathodal Transcranial Direct Current Stimulation (HD C-tDCS)Phase 2 · NCT06440707
- High-dose AnakinraPhase 2 · NCT07423975
- High-dose Xinglou Chengqi granulesPhase 2 · NCT07163702
- HRS-4029Phase 2 · NCT06905314 · NCT07739160
- hUC-MSCs treatment (high dose)Phase 2 · NCT07084012
- hUC-MSCs treatment (low dose)Phase 2 · NCT07084012
- hUCBPhase 2 · NCT06040476
- Human serum albumin infusion 20%Phase 2 · NCT07294391
- Human Urinary KallidinogenasePhase 2 · NCT07283159
- HyaluronidasePhase 2 · NCT03306615
- hyaluronidase plus salinePhase 2 · NCT06718413
- Hydroxypropyl-β-cyclodextrin injectionPhase 2 · NCT06679322
- HydroxyureaPhase 2 · NCT03948867 · NCT05953584
- HYPERCAPNIAPhase 2 · NCT05051397
- Intra-arterial SalinePhase 2 · NCT06781385
- intra-arterial tenecteplase administrationPhase 2 · NCT06904911
- Intravenous insulinPhase 2 · NCT07501533
- Ischemic ConditioningPhase 2 · NCT06930638
- Isotonic Saline SolutionPhase 2 · NCT05880524
- IxCell hUC-MSC-S (Human Umbilical Cord Mesenchymal Stem Cells)Phase 2 · NCT07197606
- J147 Emulsion for InjectionPhase 2 · NCT07430917
- Low-dose AnakinraPhase 2 · NCT07423975
- Low-dose Xinglou Chengqi granules and placeboPhase 2 · NCT07163702
- LT3001 Drug ProductPhase 2 · NCT07890298 · NCT05198323
- LT3001 Drug: low dosePhase 2 · NCT07754825
- LT3001 Drug:high dosePhase 2 · NCT07754825 · NCT05686642
- LT3001 Drug:low dosePhase 2 · NCT05686642
- MannitolPhase 2 · NCT07080567
- MaravirocPhase 2 · NCT07080567
- MT200605Phase 2 · NCT07205328
- NanO2TMPhase 2 · NCT06821347
- Nitric OxidePhase 2 · NCT03023449
- Normal saline placeboPhase 2 · NCT06339411
- NORMOCAPNIAPhase 2 · NCT05051397
- NTS-521Phase 2 · NCT07742098
- prourokinasePhase 2 · NCT07550296
- QD202Phase 2 · NCT07581210
- QHRD106 Injection (High-dose group)Phase 2 · NCT07396337
- QHRD106 Injection (Low-dose group)Phase 2 · NCT07396337
- QHRD106 Injection (Middle-dose group)Phase 2 · NCT07396337
- Real Soterix Mini-CT tDCS stimulatorPhase 2 · NCT05816603
- RehUp BCI InterventionPhase 2 · NCT06538506
- Remote ischaemic conditioningPhase 2 · NCT07914647
- Remote ischemic conditioning (RIC) progammable devicePhase 2 · NCT05967728
- RimonabantPhase 2 · NCT07913763
- RK-4 injectionPhase 2 · NCT07166380 · NCT07203521
- SalinePhase 2 · NCT07865871 · NCT06718413
- SemaglutidePhase 2 · NCT05630586 · NCT07511543
- SirolimusPhase 2 · NCT01499888 · NCT06091332
- Spironolactone PillPhase 2 · NCT04760717
- Starch flakePhase 2 · NCT06091332
- statin + ezetimibePhase 2 · NCT07307989
- Statin monotherapy (rosuvastatin or atorvastatin)Phase 2 · NCT07307989
- Stem cell TransplantationPhase 2 · NCT06752720
- StrokeWear Motor and Behavioral InterventionPhase 2 · NCT05626894
- TacrolimusPhase 2 · NCT07709845
- Tadalafil 20 MGPhase 2 · NCT05173896
- TAK-755Phase 2 · NCT07392450
- TBO-309Phase 2 · NCT05363397
- TBO-309: 120 mgPhase 2 · NCT06813651
- TBO-309: 30 mgPhase 2 · NCT06813651
- TBO-309: 60 mgPhase 2 · NCT06813651
- TelerehabilitationPhase 2 · NCT07646522
- The KPCXM18 injectionPhase 2 · NCT07279493
- The methylprednisolone sodium succinate groupPhase 2 · NCT07516522
- The placebo groupPhase 2 · NCT07516522
- TiprogrelPhase 2 · NCT06601127
- Transcranial Dirrect Current StimulationPhase 2 · NCT06516588
- Transcranial Magnetic Stimulation (TMS)Phase 2 · NCT06968663 · NCT06842745
- TS23Phase 2 · NCT05948566
- tSCSPhase 2 · NCT07334977
- Usual BP management groupPhase 2 · NCT07279259
- VERVE-102Phase 2 · NCT07839936
- XenonPhase 2 · NCT04696523
- ZenicogPhase 2 · NCT07397923
- ZuranolonePhase 2 · NCT06759558
- 1.0 × 10^6 cells/kg once every two weeks for a total of 3 dosesPhase 1/2 · NCT07896941
- 10 mg Intra-arterial VerapamilPhase 1/2 · NCT03347786
- 2.0 × 10^6 cells/kg once every two weeks for a total of 3 dosesPhase 1/2 · NCT07896941
- 20 mg Intra-arterial VerapamilPhase 1/2 · NCT03347786
- 3.0 × 10^6 cells/kg once every two weeks for a total of 3 dosesPhase 1/2 · NCT07896941
- ABMSCPhase 1/2 · NCT06997939
- Active movement trainingPhase 1/2 · NCT06404268
- AlemtuzumabPhase 1/2 · NCT01499888
- Allogeneic Non-Myeloablative Stem Cell TransplantationPhase 1/2 · NCT01499888
- Ankle robot training and functional electrical stimulation(FES) groupPhase 1/2 · NCT04550728
- Ankle robot training groupPhase 1/2 · NCT04550728
- Ankle torque and motion measurementPhase 1/2 · NCT06404268
- Arm Remote Ischemic Conditioning plus Pneumatic Compression lower limbPhase 1/2 · NCT06911385
- ASP2246Phase 1/2 · NCT07318714
- B2065Phase 1/2 · NCT07371624
- Brain state-dependent paired corticomotoneuronal stimulation (PCMS)Phase 1/2 · NCT04830163
- Brain surgeryPhase 1/2 · NCT07318714
- Conditioned MediumPhase 1/2 · NCT05008588
- CorabotasePhase 1/2 · NCT04752774
- Drug Lowering CBF and Intermittent Hypoxia SleepPhase 1/2 · NCT03255408
- Drug Lowering Cerebral Blood Flow (CBF) and Normoxia SleepPhase 1/2 · NCT03255408
- DysportPhase 1/2 · NCT04752774
- Endovascular thrombectomy combination with selective intra-arterial hypothermic magnesium sulfate infusion (350 ml).Phase 1/2 · NCT07163299
- Endovascular thrombectomy combination with selective intra-arterial hypothermic magnesium sulfate infusion (500 ml).Phase 1/2 · NCT07163299
- Endovascular thrombectomy combination with selective intra-arterial hypothermic magnesium sulfate infusion (650 ml).Phase 1/2 · NCT07163299
- Gamed-based active movement trainingPhase 1/2 · NCT06404268
- Glycerol TributyratePhase 1/2 · NCT06792500
- Human Adipose-Derived Stem Cell ExosomesPhase 1/2 · NCT07398612
- Human Placenta-derived 3D Mesenchymal Stem Cells (Guojiangqingke)Phase 1/2 · NCT07635758
- iEVPhase 1/2 · NCT07145294
- InfliximabPhase 1/2 · NCT02638701
- iNSC-EV01Phase 1/2 · NCT07143786
- MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Active)Phase 1/2 · NCT07113067
- MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Sham)Phase 1/2 · NCT07113067
- Motor relearning trainingPhase 1/2 · NCT06404268
- NCS-01Phase 1/2 · NCT03915431
- Neural Stem CellsPhase 1/2 · NCT04631406
- Neurologic and Neutrophic DrugsPhase 1/2 · NCT05008588
- Passive movementPhase 1/2 · NCT06404268
- Passive stretchingPhase 1/2 · NCT06404268
- Phase 2 Fixed-Volume Concentration-Escalation CohortPhase 1/2 · NCT07163299
- Photobiomodulation TherapyPhase 1/2 · NCT07784231
- Qingre Huatan FormulaPhase 1/2 · NCT06857487
- Qingre Huatan Formula placeboPhase 1/2 · NCT06857487
- RelaxinPhase 1/2 · NCT07359872
- Required FieldPhase 1/2 · NCT07784751
- single infusion, 1.0 × 10^6 cells/kgPhase 1/2 · NCT07896941
- single infusion, 2.0 × 10^6 cells/kgPhase 1/2 · NCT07896941
- single infusion, 3.0 × 10^6 cells/kgPhase 1/2 · NCT07896941
- Supplementation of β -sitosterolPhase 1/2 · NCT07457333
- Transcranial alternating current stimulation (tACS)Phase 1/2 · NCT07613970
- Umbilical Cord Mesenchymal Stem CellsPhase 1/2 · NCT05008588
- a placebo of extracellular vesicles derived from human induced neural stem cell for intravenous injectionPhase 1 · NCT06612710
- AB126 Neural Exosomes Intravenous InjectionPhase 1 · NCT07813130
- Adipose derived Stem CellPhase 1 · NCT03570450
- Allogeneic Umbilical Cord-Derived Mesenchymal Stromal Cells (UC-MSCs)Phase 1 · NCT07913282
- Amniotic and Umbilical Cord Tissue ProcedurePhase 1 · NCT03899298
- Botulinum toxinPhase 1 · NCT04630873
- CG-0255 Besylate CapsulePhase 1 · NCT07619885
- CG-0255 Besylate for InjectionPhase 1 · NCT07619885
- chlorpromazine and promethazinePhase 1 · NCT06663631
- cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomesPhase 1 · NCT05158101
- EksoGT™, Ekso Bionics, Berkley, CA, USAPhase 1 · NCT04309305
- extracellular vesicles derived from human induced neural stem cell for intravenous injectionPhase 1 · NCT06612710
- Human Umbilical Cord Mesenchymal Stem Cells InjectionPhase 1 · NCT07628933
- iNOPhase 1 · NCT05871606
- Intranasal Administration of Human Umbilical Cord Mesenchymal Stem Cell-Derived Small Extracellular Vesicles (hUC-MSC-sEV-001) TherapyPhase 1 · NCT07232563
- Intravenous Pump-Delivered PropranololPhase 1 · NCT07528235
- LWP779Phase 1 · NCT07371455
- Magnesium sulfatePhase 1 · NCT06956521
- Multiple dosing, AAPB for injection, intravenous dripPhase 1 · NCT06679998
- N,N-DimethyltryptaminePhase 1 · NCT05559931
- Nicotinamide riboside (NR)Phase 1 · NCT06280482
- Pegcetacoplan Injection [Empaveli]Phase 1 · NCT07495722
- Psilocybin (Usona Institute)Phase 1 · NCT07053917
- Robot-assisted stereotactic hematoma aspiration plus intrahematoma tenecteplasePhase 1 · NCT07641998
- rt-PAPhase 1 · NCT06663631
- Single dose, AAPB by injection, intravenous drip.Phase 1 · NCT06679998
- Single-pulse TMSPhase 1 · NCT06365099
- SNE-101Phase 1 · NCT06995625
- Standard Stroke Care Including Mechanical ThrombectomyPhase 1 · NCT07913282
- Vagus Nerve Stimulation in early stagePhase 1 · NCT06938243
- Vagus Nerve Stimulation in late stagePhase 1 · NCT06938243
- Bilateral Cerebellar deep brain stimulationEarly phase 1 · NCT06303960
- Botulinum Toxin Type A (BoNT-A)Early phase 1 · NCT06811142
- Direct Oral Anticoagulant (DOAC)Early phase 1 · NCT07011095
- End-effector assistanceEarly phase 1 · NCT07011173
- enteric-coated aspirin tablets (100 mg once daily, Bayer Healthcare, specification: 100 mg/tablet)Early phase 1 · NCT07205250
- Exotendon assistanceEarly phase 1 · NCT07011173
- Inhaled colistinEarly phase 1 · NCT07865871
- Inhaled treprostinilEarly phase 1 · NCT07116681
- Intra-arterial hypothermic magnesium sulfate infusionEarly phase 1 · NCT06760195
- intracerebral stereotactic injection of NXL-001Early phase 1 · NCT06761183
- Ivabradine (single oral dose)Early phase 1 · NCT07717710
- Ketone Monoester (KE)Early phase 1 · NCT06108076
- Memantine XREarly phase 1 · NCT02144584
- NaF PET-CTEarly phase 1 · NCT06961604
- Telmisartan, Metformin, CilostazolEarly phase 1 · NCT07588932
- TizanidineEarly phase 1 · NCT06666673
- Transcutaneous Electrical StimulationEarly phase 1 · NCT04755699
- Unilateral Cerebellar deep brain stimulationEarly phase 1 · NCT06303960
- Vagus Nerve StimulationEarly phase 1 · NCT06303960
- Visual ROM augmentationEarly phase 1 · NCT07598695
- Visual ROM reductionEarly phase 1 · NCT07598695
- VKAEarly phase 1 · NCT07011095
Closest to patients
- Assessment of Flecainide to Lower the Patent Foramen Ovale Closure Risk of Atrial Arrhythmia or TachycardiaAssessment of Flecainide to Lower the Patent Foramen Ovale Closure Risk of Atrial Arrhythmia or TachycardiaHopital Pitie-Salpetriere · Paris, FrancePhase 3Primary completion 2024
- Enhancement of Stroke Rehabilitation With LevodopaEnhancement of Stroke Rehabilitation With LevodopaRheinburg Klinik AG · Walzenhausen, Switzerland + 23 more hospitalsPhase 3Primary completion 2024
- Anticoagulation Therapy in Non-device-related Intra-cardiac ThrombusAnticoagulation Therapy in Non-device-related Intra-cardiac ThrombusCHU Limoges · Limoges, France + 34 more hospitalsPhase 3Primary completion 2025
Let us optimize your content
Apply for experimental treatment or a research study
The trial team decides who can take part; your doctor can help you ask.
Distance is calculated in your browser. Your city is not sent to us.
Loading trial sites…
Latest news
Results, new trials and publications, newest first. Every item links to its source.
Results and new studies, newest first, in plain words.
Plain-language summary pending. Original title shown.
Publication
Eicosapentaenoic acid in adipose tissue is associated with a lower risk of hemorrhagic stroke: A Danish case-cohort study.
Eicosapentaenoic acid in adipose tissue is associated with a lower risk of hemorrhagic stroke: A Danish case-cohort study.
The Journal of nutrition
PubMed · PMID 42971357Publication
Effect of Atorvastatin and Rosuvastatin on Lipid Parameters and Inflammatory Biomarkers in Patients with Acute Coronary Syndrome: A Systematic Review and Meta-Analysis.
Effect of Atorvastatin and Rosuvastatin on Lipid Parameters and Inflammatory Biomarkers in Patients with Acute Coronary Syndrome: A Systematic Review and Meta-Analysis.
Cardiology in review
PubMed · PMID 42957597Publication
Sex Differences in Stress Reactivity and Dementia Risk: A Pilot Study of Older Adults With Problematic or Frequent Cannabis Use.
Sex Differences in Stress Reactivity and Dementia Risk: A Pilot Study of Older Adults With Problematic or Frequent Cannabis Use.
Journal of geriatric psychiatry and neurology
PubMed · PMID 42960557Case report
Acute ischemic stroke associated with Moringa oleifera and protein powder consumption in a patient on warfarin: A coagulation paradox and clinical blind spot.
Acute ischemic stroke associated with Moringa oleifera and protein powder consumption in a patient on warfarin: A coagulation paradox and clinical blind spot.
Surgical neurology international
PubMed · PMID 42974563
Find fellow researchers
Groups with active Stroke work.
Capital Medical University
Beijing, China
Team details appear once the team leader joins.
Is this your team? Claim it
Massachusetts General Hospital
Boston, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Johns Hopkins University
Baltimore, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Mayo Clinic
Rochester, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Yale University
New Haven, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Inserm
Paris, France
Team details appear once the team leader joins.
Is this your team? Claim it
Fudan University
Shanghai, China
Team details appear once the team leader joins.
Is this your team? Claim it
University of Toronto
Toronto, Canada
Team details appear once the team leader joins.
Is this your team? Claim it
University of California, Los Angeles
Los Angeles, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Brigham and Women's Hospital
Boston, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Zhejiang University
Hangzhou, China
Team details appear once the team leader joins.
Is this your team? Claim it